Nanexa AB (publ) (NANEXA) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome. Nanexa, the drug delivery company, has released a report for the second quarter of 2025. In the studio we of course have David Wessberg, who is the CEO of Nanexa. Welcome David. Thank you very much. What would you say has been the focus during the quarter? Of course, a focus on the GLP-1s, Nexio 2 of course, and a lot of focus on commercialization, agreements, discussions with different companies. So it has been a very intense quarter, I can say. And we have already provided some results on Nexio 2, so we can come back to that later. But in short, that's it. Thank you very much. Let's look at some figures before we move on and look a little more in detail at what you mentioned. The turnover in the quarter is halved to about 2.7 million Swedish kronor against 5.6 last year. Is this in line with your expectations? Yes, there will always be this type of fluctuation, but it is completely in line. Losses decrease somewhat, liquid funds at the start of the period land on 40 million SEK and that is also in line with the opposite period last year. Yes, the economy is completely in line with how we have planned. There is not much to comment on that, but it is in line. We got this grant from Applied Materials, for example. There are a few of them who have made cover option solutions here during June and July as well, which gave us 3.5 million in total. But I think it's good. The biggest focus is on NEXT22, the monthly dose of liraglutide, a GLP-1 substance for patients with type 2 diabetes and obesity. How would you describe the development during the quarter? What we did during the quarter, if you remember, we delivered data on three doses where the highest was 10 mg. We continued into the 30 mg dose, which was an addition to the study we did and we have had very goo...